Treating severe asthma: Targeting the IL‐5 pathway
Research output: Contribution to journal › Review › Research › peer-review
Standard
Treating severe asthma : Targeting the IL‐5 pathway. / Principe, Stefania; Porsbjerg, Celeste; Bolm Ditlev, Sisse; Kjærsgaard Klein, Ditte; Golebski, Korneliusz; Dyhre‐petersen, Nanna; Dijk, Yoni E.; Bragt, Job J.m.h.; Dankelman, Lente L.h.; Dahlen, Sven‐erik; Brightling, Christopher E.; Vijverberg, Susanne J.h.; Maitland‐van Der Zee, Anke H.
In: Clinical and Experimental Allergy, Vol. 51, No. 8, 01.08.2021, p. 992-1005.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Treating severe asthma
T2 - Targeting the IL‐5 pathway
AU - Principe, Stefania
AU - Porsbjerg, Celeste
AU - Bolm Ditlev, Sisse
AU - Kjærsgaard Klein, Ditte
AU - Golebski, Korneliusz
AU - Dyhre‐petersen, Nanna
AU - Dijk, Yoni E.
AU - Bragt, Job J.m.h.
AU - Dankelman, Lente L.h.
AU - Dahlen, Sven‐erik
AU - Brightling, Christopher E.
AU - Vijverberg, Susanne J.h.
AU - Maitland‐van Der Zee, Anke H.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Severe asthma is a heterogeneous disease with different phenotypes based on clinical, functional or inflammatory parameters. In particular, the eosinophilic phenotype is associated with type 2 inflammation and increased levels of interleukin (IL)-4, IL-5 and IL-13). Monoclonal antibodies that target the eosinophilic inflammatory pathways (IL-5R and IL-5), namely mepolizumab, reslizumab, and benralizumab, are effective and safe for severe eosinophilic asthma. Eosinophils threshold represents the most indicative biomarker for response to treatment with all three monoclonal antibodies. Improvement in asthma symptoms scores, lung function, the number of exacerbations, history of late-onset asthma, chronic rhinosinusitis with nasal polyposis, low oral corticosteroids use and low body mass index represent predictive clinical markers of response. Novel Omics studies are emerging with proteomics data and exhaled breath analyses. These may prove useful as biomarkers of response and non-response biologics. Moreover, future biomarker studies need to be undertaken in paediatric patients affected by severe asthma. The choice of appropriate biologic therapy for severe asthma remains challenging. The importance of finding biomarkers that can predict response continuous an open issue that needs to be further explored. This review describes the clinical effects of targeting the IL-5 pathway in severe asthma in adult and paediatric patients, focusing on predictors of response and non-response.
AB - Severe asthma is a heterogeneous disease with different phenotypes based on clinical, functional or inflammatory parameters. In particular, the eosinophilic phenotype is associated with type 2 inflammation and increased levels of interleukin (IL)-4, IL-5 and IL-13). Monoclonal antibodies that target the eosinophilic inflammatory pathways (IL-5R and IL-5), namely mepolizumab, reslizumab, and benralizumab, are effective and safe for severe eosinophilic asthma. Eosinophils threshold represents the most indicative biomarker for response to treatment with all three monoclonal antibodies. Improvement in asthma symptoms scores, lung function, the number of exacerbations, history of late-onset asthma, chronic rhinosinusitis with nasal polyposis, low oral corticosteroids use and low body mass index represent predictive clinical markers of response. Novel Omics studies are emerging with proteomics data and exhaled breath analyses. These may prove useful as biomarkers of response and non-response biologics. Moreover, future biomarker studies need to be undertaken in paediatric patients affected by severe asthma. The choice of appropriate biologic therapy for severe asthma remains challenging. The importance of finding biomarkers that can predict response continuous an open issue that needs to be further explored. This review describes the clinical effects of targeting the IL-5 pathway in severe asthma in adult and paediatric patients, focusing on predictors of response and non-response.
U2 - 10.1111/cea.13885
DO - 10.1111/cea.13885
M3 - Review
C2 - 33887082
VL - 51
SP - 992
EP - 1005
JO - Clinical Allergy
JF - Clinical Allergy
SN - 0954-7894
IS - 8
ER -
ID: 280235578